within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP52_DasabuvirOmbitasvirParitaprevirA;

model DasabuvirOmbitasvirParitaprevirA
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 4.194444444444445e-06,
    adminDuration = 600,
    adminMass = 25 / 1000000,
    adminCount = 1,
    Vd = 0.103,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016833333333333332,
    Tlag = 12.0,
    Vdp = 0.062,
    k12 = 1.8055555555555555e-05,
    k21 = 1.8055555555555555e-05);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>DasabuvirOmbitasvirParitaprevirAndRitonavir</td></tr><tr><td>ATC code:</td><td>J05AP52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dasabuvir, ombitasvir, paritaprevir, and ritonavir is a fixed-dose combination regimen used as antiviral therapy for chronic hepatitis C virus (HCV) infection. Paritaprevir (an NS3/4A protease inhibitor) is boosted with ritonavir (a CYP3A inhibitor), ombitasvir is an NS5A inhibitor, and dasabuvir is a non-nucleoside NS5B polymerase inhibitor. This fixed combination (also marketed as Viekira Pak) is approved for the treatment of HCV genotype 1 and was widely used but has been largely superseded by newer regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult subjects after oral administration (fed state). Parameters are predominantly derived from population PK and single/multiple dose studies.</p><h4>References</h4><ol><li><p>Mensing, S, et al., &amp; Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. <i>The AAPS journal</i> 18(1) 270–280. DOI:<a href=\"https://doi.org/10.1208/s12248-015-9846-1\">10.1208/s12248-015-9846-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26597291/\">https://pubmed.ncbi.nlm.nih.gov/26597291</a></p></li><li><p>Minaei, AA, &amp; Kowdley, KV (2015). ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. <i>Expert opinion on pharmacotherapy</i> 16(6) 929–937. DOI:<a href=\"https://doi.org/10.1517/14656566.2015.1024653\">10.1517/14656566.2015.1024653</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25800085/\">https://pubmed.ncbi.nlm.nih.gov/25800085</a></p></li><li><p>Brayer, SW, &amp; Reddy, KR (2015). Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. <i>Expert review of gastroenterology &amp; hepatology</i> 9(5) 547–558. DOI:<a href=\"https://doi.org/10.1586/17474124.2015.1032938\">10.1586/17474124.2015.1032938</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25846301/\">https://pubmed.ncbi.nlm.nih.gov/25846301</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AP52 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end DasabuvirOmbitasvirParitaprevirA;
